IRVINE, Calif.--(BUSINESS WIRE)--Cobalis Corp. (OTC BB: CLSC), a pharmaceutical development company specializing in anti-allergy medications, announced today that its Patent Application No. 2001-006297, titled “Cyanocobalamin Treatment in Allergic Disease,” has been allowed by the Mexican Patent Office. The patent protects the method of treatment underlying Cobalis’ PreHistin™ anti-allergy medication in Mexico and adds to Cobalis’ patent portfolio consisting of patents issued in the U.S., E.U., and Australia and patents pending in Japan and Canada.
